BRAIN Biotech

Update in progress

BNN.DE (XETRA)

Company RatingNeutral
SectorBasic Materials
IndustrySpecialty Chemicals

BRAIN Biotech AG develops bio-based products in Germany, the US, France, the Netherlands and the United Kingdom. It operates in two segments: BRAINBiocatalysts, which develops, produces and markets enzymes, microorganisms and ingredients; and BRAINBioIncubator, a pipeline of R&D projects for the life sciences industry. Its offerings support foods, animal feed, cosmetics, medical products, and industrial applications. Founded 1993, headquartered in Zwingenberg, Germany; renamed in 2021.

Company score

Sentiment: 0.40; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.24; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.13; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.00; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.12; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.26; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive